IGF2 and cancer: Patients with 11p15 telomeric domain defects (H19/IGF2:IG-DMR -GOM and UPD) have a higher risk of developing cancer compared to cases presenting centromeric aberrations (KCNQ1OT1:TSS-DMR-LOM mutation and CDKN1C) (Soejima and Higashimoto, 2013; Maas et al., 2016).